Specialty pharmaceutical and consumer healthcare company Norgine announced on Friday the validation of X4 Pharmaceuticals' Marketing Authorization Application for mavorixafor by the European Medicines Agency's Committee for Medicinal Products for Human Use.

Mavorixafor, an oral, once-daily treatment for WHIM syndrome, was approved by the US Food and Drug Administration in April 2024 under the name XOLREMDI for patients aged 12 and older.

This regulatory progress follows a licensing agreement between Norgine and X4 Pharmaceuticals. Efforts are underway to facilitate access to mavorixafor in Europe, Australia and New Zealand. Achieving this milestone represents a significant step toward addressing the needs of patients with this rare primary immunodeficiency.